Hidalgo, Manuel

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 6,712

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 3,969

Pancreatic cancer

Hidalgo, M. (2010) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 2,570

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 1,764

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 1,125

DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 1,081

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 1,001

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology

Head and Neck Cancer StudiesHER2/EGFR in Cancer Research

Cited by 807

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology

DNA Repair MechanismsCancer-related Molecular Pathways

Cited by 381

Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer

Shain, A. H., Giacomini, C. P., Matsukuma, K., Karikari, C. A., Bashyam, M. D., Hidalgo, M., Maitra, A., & Pollack, J. R. (2012) · Proceedings of the National Academy of Sciences

Chromatin Remodeling and CancerPancreatic and Hepatic Oncology Research

Cited by 221

Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function

Rajeshkumar, N. V., Dutta, P., Yabuuchi, S., de Wilde, R. F., Martinez, G. V., Le, A., Kamphorst, J. J., Rabinowitz, J. D., Jain, S. K., Hidalgo, M., et al. (2015) · Cancer Research

Cancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology Research

Cited by 158

Afatinib restrains K-RAS–driven lung tumorigenesis

Moll, H. P., Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., et al. (2018) · Science Translational Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 125

c-RAF ablation induces regression of advanced Kras/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling

Sanclemente, M., Francoz, S., Esteban-Burgos, L., Bousquet-Mur, E., Djurec, M., Lopez-Casas, P. P., Hidalgo, M., Guerra, C., Drosten, M., Musteanu, M., et al. (2018) · Cancer Cell

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 119

Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF

Blasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 115

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

Van Cutsem, E., Hidalgo, M., Canon, J., Macarulla, T., Bazin, I., Poddubskaya, E., Manojlovic, N., Radenkovic, D., Verslype, C., Raymond, E., et al. (2018) · International Journal of Cancer

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 104

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

Schram, A. M., Gandhi, L., Mita, M. M., Damstrup, L., Campana, F., Hidalgo, M., Grande, E., Hyman, D. M., & Heist, R. S. (2018) · British Journal of Cancer

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways

Cited by 96

Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT/KEYNOTE-202 trial

Bockorny, B., Macarulla, T., Semenisty, V., Borazanci, E., Feliu, J., Ponz-Sarvise, M., Abad, D. G., Oberstein, P., Alistar, A., Muñoz, A., et al. (2021) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 92

Phase IB Trial of the Anti‐Cancer Stem Cell DLL4‐Binding Agent Demcizumab with Pemetrexed and Carboplatin as First‐Line Treatment of Metastatic Non‐Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L., et al. (2018) · Targeted Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 74

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 59

Precision Promise (PrP): an adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC)

Picozzi, V. J., Duliege, A.-M., Collisson, E. A., Maitra, A., Hidalgo, M., Hendifar, A. E., Beatty, G. L., Doss, S., Matrisian, L. M., Herena, P. S., et al. (2022) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchStatistical Methods in Clinical Trials

Cited by 9